TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Benzinga Logo Benzinga By Vandana Singh
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences reported strong Q3 earnings, beating consensus estimates with $2.47 per share and $7.77 billion in revenues. HIV product sales increased 4% to $5.3 billion, and the company raised fiscal 2025 guidance, highlighting potential product launches in 2026.

Insights
AAPL   neutral

Dealing with weaker Chinese demand but optimistic about future iPhone sales


GILD   positive

Beat earnings expectations, raised fiscal guidance, strong HIV drug sales, promising clinical pipeline, and positive analyst ratings from Needham and Cantor Fitzgerald